{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:00Z","timestamp":1786998360734,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ygyno.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:00:17Z","timestamp":1771012817000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts"],"prefix":"10.1016","volume":"206","author":[{"given":"Luca","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias M.P.","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Ettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ottum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1102\/1470-7330.2013.0011","article-title":"Typical and atypical metastatic sites of recurrent endometrial carcinoma","volume":"13","author":"Kurra","year":"2013","journal-title":"Cancer Imaging"},{"issue":"23","key":"10.1016\/j.ygyno.2026.02.004_bb0015","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2026.02.004_bb0020","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.004_bb0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without Olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.02.004_bb0030","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.004_bb0035","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.3390\/curroncol31110522","article-title":"Antibody-drug conjugates: a start of a new era in gynecological cancers","volume":"31","author":"Fasih","year":"2024","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.02.004_bb0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17512433.2025.2535178","article-title":"Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers","volume":"18","author":"Ettorre","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ygyno.2026.02.004_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-9929-3_1","article-title":"An overview of the current ADC discovery landscape","volume":"2078","author":"Tumey","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.004_bb0050","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1124\/dmd.114.058586","article-title":"Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates","volume":"42","author":"Han","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.004_bb0060","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1073\/pnas.0806514106","article-title":"Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation","volume":"106","author":"Salvesen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","article-title":"Structure and dynamics of the EGFR\/HER2 heterodimer","volume":"9","author":"Bai","year":"2023","journal-title":"Cell Discov."},{"issue":"16","key":"10.1016\/j.ygyno.2026.02.004_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells14161282","article-title":"HER2\/neu as a signaling and therapeutic marker in uterine serous carcinoma","volume":"14","author":"Ettorre","year":"2025","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.004_bb0075","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.004_bb0080","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jamaoncol.2024.3660","article-title":"Frequency of ERBB2-low expression in endometrial cancer","volume":"10","author":"Krakstad","year":"2024","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.02.004_bb0085","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.004_bb0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.004_bb0095","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.clbc.2020.08.006","article-title":"Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer","volume":"21","author":"Andrikopoulou","year":"2021","journal-title":"Clin. Breast Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.004_bb0100","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.004_bb0115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/1535-7163.MCT-23-0126","article-title":"In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma","volume":"22","author":"Mutlu","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2026.02.004_bb0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2022.12.018","article-title":"Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/neu expression","volume":"170","author":"Mauricio","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.004_bb0125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.bjc.6605448","article-title":"In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma","volume":"102","author":"El-Sahwi","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10585-013-9614-5","article-title":"Class III \u03b2-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin\/paclitaxel","volume":"31","author":"Roque","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.004_bb0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/IGC.0b013e31820cc305","article-title":"The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?","volume":"21","author":"Abu-Rustum","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.02.004_bb0145","unstructured":"G. Turashvili, et al., Reporting results of biomarker testing of specimens from patients with carcinoma of gynecologic origin: the updated college of American pathologists protocol, Arch. Pathol. Lab Med. (2025); ahead of print; 2\u20136"},{"key":"10.1016\/j.ygyno.2026.02.004_bb0150","doi-asserted-by":"crossref","unstructured":"N. Buza, The rapidly evolving landscape of human epidermal growth factor receptor 2 (HER2) testing in endometrial carcinoma and other gynecologic malignancies, Arch. Pathol. Lab Med. (2025); ahead of print; 1\u20136","DOI":"10.5858\/arpa.2025-0046-RA"},{"issue":"20","key":"10.1016\/j.ygyno.2026.02.004_bb0155","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.02.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ygyno.2026.02.004_bb0165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/adt.2005.3.525","article-title":"Assessing the minimum number of data points required for accurate IC50 determination","volume":"3","author":"Turner","year":"2005","journal-title":"Assay Drug Dev. Technol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ygyno.2026.02.004_bb0180","first-page":"103","article-title":"Spotlight on trastuzumab deruxtecan (DS-8201,T-DXd) for HER2 mutation positive non-small cell lung cancer","volume":"12","author":"Azar","year":"2021","journal-title":"Lung Cancer (Auckl)"},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.004_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100299","article-title":"HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer","volume":"36","author":"Shen","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2026.02.004_bb0190","doi-asserted-by":"crossref","unstructured":"E. Menshikova, et al., Analysis of HER2 heterogeneity at the protein and gene levels in endometrial cancer: refining HER2 reporting and HER2-directed therapies, Lab. Investig. 104240 (2025); 105; 12.","DOI":"10.1016\/j.labinv.2025.104240"},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.004_bb0195","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.02.004_bb0200","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosom. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.004_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.02.004_bb0210","doi-asserted-by":"crossref","unstructured":"Curigliano G, et al. Trastuzumab deruxtecan vs physician\u2019s choice of chemotherapy in hormone receptor\u2013positive, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: Primary results from DESTINY-Breast06. J Clin Oncol. 2024;42(17_suppl):LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000"},{"key":"10.1016\/j.ygyno.2026.02.004_bb0215","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2026.02.004_bb0220","author":"DaiichiSankyo"},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.004_bb0225","doi-asserted-by":"crossref","first-page":"396.e1","DOI":"10.1016\/j.ajog.2020.02.021","article-title":"Impact of quality of care on racial disparities in survival for endometrial cancer","volume":"223","author":"Huang","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.004_bb0230","first-page":"1017","article-title":"Racial and ethnic differences in tumor characteristics among endometrial cancer patients in an equal-access healthcare population","volume":"34","author":"Desmond","year":"2023","journal-title":"Cancer Causes Control"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826007882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826007882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:21:47Z","timestamp":1782926507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826007882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"alternative-id":["S0090825826007882"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.02.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}